Sionna Therapeutics Stock Plunges After Cystic Fibrosis Trial Failure; Vertex Rises on Reduced Competition Will not advance SION-719 add-on; Vertex sees relief from rivalry. "Trikafta." Credit: Vertex Pharmaceuticals Subscribe now Already have an account? Sign in.
